MAGED4 expression in glioma and upregulation in glioma cell lines with 5-aza-2'-deoxycytidine treatment.

Melanoma-associated antigen (MAGE) family genes have been considered as potentially promising targets for anticancer immunotherapy. MAGED4 was originally identified as a glioma-specific antigen. Current knowledge about MAGED4 expression in glioma is only based on mRNA analysis and MAGED4 protein expression has not been elucidated. In the present study, we investigated this point and found that MAGED4 mRNA and protein were absent or very lowly expressed in various normal tissues and glioma cell line SHG44, but overexpressed in glioma cell lines A172,U251,U87-MG as well as glioma tissues, with significant heterogeneity. Furthermore, MAGED4 protein expression was positively correlated with the glioma type and grade. We also found that the expression of MAGED4 inversely correlated with the overall methylation status of the MAGED4 promoter CpG island. Furthermore, when SHG44 and A172 with higher methylation were treated with the DNA demethylating agent 5-aza-2'-deoxycytidine (5-AZA-CdR) reactivation of MAGED4 mRNA was mediated by significant demethylation in SHG44 instead of A172. However, 5-AZA-CdR treatment had no effect on MAGED4 protein in both SHG44 and A172 cells. In conclusion, MAGED4 is frequently and highly expressed in glioma and is partly regulated by DNA methylation. The results suggest that MAGED4 might be a promising target for glioma immunotherapy combined with 5-AZA-CdR to enhance its expression and eliminate intratumor heterogeneity.

[1]  J. Le Pecq,et al.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer , 2005, Journal of Translational Medicine.

[2]  H. Rammensee,et al.  MAGED4 – expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue , 2005, Cancer biology & therapy.

[3]  B. Seliger,et al.  5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  F. Garrido,et al.  Methylated CpG points identified within MAGE‐1 promoter are involved in gene repression , 1996, International journal of cancer.

[5]  M. Herlyn,et al.  Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. , 1994, Cancer research.

[6]  D L Morton,et al.  Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. , 1997, The American journal of pathology.

[7]  A. Sood,et al.  EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma , 2004, Clinical Cancer Research.

[8]  Xiaoxun Xie,et al.  Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters. , 2013, International journal of clinical and experimental pathology.

[9]  M. Maio,et al.  Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous Melanoma , 2002, Journal of immunotherapy.

[10]  L. O’Driscoll,et al.  MAGE‐D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis , 2012, International journal of cancer.

[11]  K. Mimori,et al.  The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. , 1995, Gastroenterology.

[12]  D. Bigner,et al.  Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Peng Huang,et al.  Soluble expression of recombinant human SMP30 for detecting serum SMP30 antibody levels in hepatocellular carcinoma patients. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[14]  Yi Li,et al.  Antitumor activity of lentivirus-mediated interleukin -12 gene modified dendritic cells in human lung cancer in vitro. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[15]  Wei Zhang,et al.  UHRF2 mRNA expression is low in malignant glioma but silencing inhibits the growth of U251 glioma cells in vitro. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[16]  K. Pantel,et al.  Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells , 2006, Molecular Cancer Research.

[17]  L. Liau,et al.  Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. , 2003, Cancer research.

[18]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[19]  N. Ozkan,et al.  Cyclin D1 gene G870A variants and primary brain tumors. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[20]  Jian Yu,et al.  A novel protein-DNA interaction involved with the CpG dinucleotide at −30 upstream is linked to the DNA methylation mediated transcription silencing of the MAGE-A1 gene , 2004, Cell Research.

[21]  A. V. van Kessel,et al.  Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. , 2000, Cancer research.

[22]  K. Lillehei,et al.  Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[23]  D. Meek,et al.  MAGE-A antigens as targets in tumour therapy. , 2012, Cancer letters.

[24]  S. Teo,et al.  Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome. , 2012, Cancer letters.

[25]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[26]  K. Shimizu,et al.  Structural characterization and chromosomal localization of the MAGE-E1 gene. , 2001, Gene.

[27]  J. Teruya-Feldstein,et al.  Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. , 2003, Cancer immunity.

[28]  G. Cornelis,et al.  A MAGE‐A4 peptide presented by HLA‐A2 is recognized by cytolytic T lymphocytes , 1999, European journal of immunology.

[29]  M. Maio,et al.  Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine , 2004, Cancer Research.

[30]  Fumihiro Tanaka,et al.  Expression of MAGE-D4, a novel MAGE family antigen, is correlated with tumor-cell proliferation of non-small cell lung cancer. , 2006, Lung cancer.

[31]  Sufang Zhou,et al.  Knockdown of OY‐TES‐1 by RNAi causes cell cycle arrest and migration decrease in bone marrow‐derived mesenchymal stem cells , 2012, Cell biology international.

[32]  Burkhard Becher,et al.  Brain‐immune connection: Immuno‐regulatory properties of CNS‐resident cells , 2000, Glia.

[33]  P. Kleihues,et al.  Epidemiology and etiology of gliomas , 2005, Acta Neuropathologica.

[34]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[35]  S. U. Kim,et al.  MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. , 2001, Cancer research.